In fact, we’ve invested more than $3 billion in R&D globally over the last five years. And whether we’re developing more affordable versions of insulins, biologics or respiratory therapies, better health for a better world is our goal.
Innovation occurs around the clock in multiple R&D sites worldwide. Mylan has:
including one in Texas and one in Vermont
R&D, Clinical, Medical and Regulatory professionals worldwide
Mylan takes on challenges no one else will, developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more.
For example, lack of refrigeration once meant lack of access to certain antiretroviral (ARV) medicines for millions of HIV/AIDS patients in developing countries. Our scientists responded by making heat-stable formulations.
And Mylan's innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.
oral solid doses, such as tablets and capsules
units of injectables
units of complex products, such as transdermal patches, topical products and respiratory therapies
From tablets and capsules, injectables and ointments to inhalers and transdermals – Mylan provides patients the medicine they need, the way they need it.
Mylan is known for producing "difficult-to-develop" medicines. Many are used to treat diseases like cancer, autoimmune disorders, chronic obstructive pulmonary disease (COPD) and diabetes.
Mylan has ~20 biosimilar and insulin analog products on the market or in development worldwide.
Read more about: